nDatalyze Corp. (NDATF) — AI Stock Analysis

nDatalyze Corp. is a healthcare company focused on applying machine learning to mental health. Their primary product, Sigmund, is an online application designed to improve the accuracy of mental health diagnoses and prescriptions.

Company Overview

TL;DR:

nDatalyze Corp. develops and offers Sigmund, a machine-learning-based application targeting inefficiencies in the mental health system. By leveraging AI to predict mental health conditions, nDatalyze aims to address misdiagnosis and misprescription, positioning itself in the emerging digital health solutions market.

About NDATF

nDatalyze Corp., formerly known as MedXtractor Corp., was founded in 2018 and is headquartered in Calgary, Canada. The company focuses on developing technology-driven solutions for the mental health sector. Its core product, Sigmund, is a machine-learning application designed to analyze patient data and predict potential mental health conditions. The goal is to improve diagnostic accuracy and reduce instances of misprescription within the mental health system. Sigmund is an online platform intended for use by healthcare professionals to aid in their assessment and treatment planning processes. nDatalyze aims to capitalize on the growing demand for digital health solutions and the increasing recognition of the importance of mental health. The company's strategic focus is on refining its machine learning algorithms and expanding the reach of the Sigmund platform within the healthcare industry. By leveraging data-driven insights, nDatalyze seeks to contribute to more effective and personalized mental healthcare.

Investment Thesis

nDatalyze Corp. presents a speculative investment opportunity within the digital health space, predicated on the potential of its Sigmund platform. The company's focus on applying machine learning to mental health diagnostics addresses a critical need for improved accuracy and efficiency in the healthcare system. Key value drivers include the continued refinement of Sigmund's algorithms, expansion of its user base among healthcare providers, and potential partnerships with larger healthcare organizations. However, the company's negative ROE of -59.8% and negative Free Cash Flow of $-0.00B highlight the early stage and high-risk nature of this investment. Successful commercialization of Sigmund and achievement of profitability are crucial for realizing the company's potential. The company's beta of 0.59 suggests lower volatility than the overall market.

Industry Context

The health information services industry is experiencing rapid growth, driven by increasing adoption of digital health solutions and the need for improved healthcare efficiency. Companies like nDatalyze are positioned to benefit from the growing demand for AI-powered diagnostic tools. The competitive landscape includes established players in the electronic health records (EHR) market, as well as emerging startups focused on specific applications of AI in healthcare. nDatalyze's success will depend on its ability to differentiate Sigmund and demonstrate its value proposition to healthcare providers.

Health Information Services

Healthcare

Growth Opportunities

Expansion of Sigmund's User Base: nDatalyze can grow by expanding the adoption of Sigmund among healthcare providers, including psychiatrists, psychologists, and general practitioners. This involves targeted marketing efforts, demonstrations of the platform's capabilities, and integration with existing EHR systems. The market for mental health software is projected to reach billions of dollars in the coming years, providing a significant opportunity for growth.
Partnerships with Healthcare Organizations: Collaborating with hospitals, clinics, and mental health institutions can provide nDatalyze with access to a larger patient population and valuable data for refining Sigmund's algorithms. Strategic partnerships can also enhance the company's credibility and market reach. These partnerships could be structured as pilot programs, licensing agreements, or joint ventures, with timelines varying based on the specific agreement.
Integration with Telehealth Platforms: Integrating Sigmund with telehealth platforms can extend its reach to patients in remote areas and improve access to mental healthcare. Telehealth is experiencing rapid growth, driven by increasing demand for convenient and affordable healthcare services. This integration could involve developing APIs or embedding Sigmund's functionality within existing telehealth applications, with potential integration timelines of 12-18 months.
Development of New AI-Powered Features: nDatalyze can enhance Sigmund's capabilities by developing new AI-powered features, such as personalized treatment recommendations, early detection of mental health conditions, and predictive analytics for patient outcomes. These features can differentiate Sigmund from competing platforms and attract new users. Development timelines for new features could range from 6-12 months, depending on the complexity and data requirements.
Geographic Expansion: nDatalyze can expand its operations beyond North America and target international markets with a growing need for mental health solutions. This involves adapting Sigmund to different languages and cultural contexts, as well as navigating regulatory requirements in each market. International expansion could be phased in over several years, starting with countries with similar healthcare systems and regulatory frameworks.

Focus on applying machine learning to improve mental health diagnostics.
Sigmund platform aims to reduce misdiagnosis and misprescription.
Headquartered in Calgary, Canada, indicating a North American market focus.
Negative ROE of -59.8% reflects current unprofitability.
Beta of 0.59 suggests lower volatility compared to the market.

What They Do

Applies machine learning to a records database.
Predicts probable mental health conditions.
Offers Sigmund, a machine-learning-based online mental health application.
Targets the mental health system to address misdiagnosis.
Aims to reduce misprescription of medications.
Provides technology-based solutions for mental healthcare.

Business Model

Software as a Service (SaaS) model, licensing Sigmund to healthcare providers.
Potential for subscription-based revenue.
Data analytics services, providing insights to healthcare organizations.
Partnerships and integrations with telehealth platforms.

Psychiatrists
Psychologists
General Practitioners
Hospitals and Clinics
Mental Health Institutions

Proprietary machine learning algorithms.
Growing database of mental health records.
First-mover advantage in applying AI to mental health diagnostics.
Potential for network effects as more users adopt Sigmund.

Catalysts

Upcoming: Publication of clinical studies demonstrating Sigmund's effectiveness.
Upcoming: Regulatory approvals for Sigmund in key markets.
Ongoing: Expansion of Sigmund's user base among healthcare providers.
Ongoing: Development of new AI-powered features for Sigmund.

Risks

Potential: Failure to achieve profitability and positive cash flow.
Potential: Competition from established players in the EHR market.
Potential: Regulatory hurdles and data privacy concerns.
Ongoing: Dependence on a single product (Sigmund).
Ongoing: Small market capitalization and limited liquidity.

Strengths

Proprietary machine learning technology.
Focus on a specific problem in the mental health system.
Potential for scalability through SaaS model.
Experienced management team with expertise in AI and healthcare.

Weaknesses

Limited operating history.
Negative profitability and cash flow.
Dependence on a single product (Sigmund).
Small market capitalization.

Opportunities

Growing demand for digital mental health solutions.
Potential for partnerships with larger healthcare organizations.
Expansion into new geographic markets.
Development of new AI-powered features.

Threats

Competition from established players in the EHR market.
Regulatory hurdles and data privacy concerns.
Risk of technological obsolescence.
Difficulty attracting and retaining qualified personnel.

Competitors & Peers

Unknown — Unknown — (Unknown)

Key Metrics

Volume: 0
MoonshotScore: 47/100

AI Insight

AI analysis pending for NDATF

OTC Tier: OTC Other
Disclosure Status: Unknown

Questions & Answers

What does nDatalyze Corp. do?

nDatalyze Corp. is a technology company focused on the mental health sector. They have developed Sigmund, a machine-learning-based application designed to improve the accuracy of mental health diagnoses and prescriptions. By analyzing patient data, Sigmund aims to assist healthcare professionals in making more informed decisions, ultimately leading to better patient outcomes. The company's business model revolves around licensing Sigmund to healthcare providers and potentially offering data analytics services to healthcare organizations.

What do analysts say about NDATF stock?

As of 2026-03-17, there is no readily available analyst consensus on NDATF stock. Given the company's small market capitalization and early stage of development, it is not widely covered by major financial analysts. Key valuation metrics, such as price-to-earnings ratio, are not applicable due to the company's current lack of profitability. Investors should carefully consider the company's growth potential and risk factors before making any investment decisions.

What are the main risks for NDATF?

The main risks for nDatalyze Corp. include its limited operating history, negative profitability, and dependence on a single product (Sigmund). The company faces competition from established players in the EHR market and must navigate regulatory hurdles and data privacy concerns. Additionally, the company's small market capitalization and limited liquidity make it a high-risk investment. Successful commercialization of Sigmund and achievement of profitability are crucial for the company's long-term survival.

Is NDATF a good investment right now?

Use the AI score and analyst targets on this page to evaluate nDatalyze Corp. (NDATF). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for NDATF?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates nDatalyze Corp. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find NDATF financial statements?

nDatalyze Corp. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about NDATF?

Analyst consensus targets and ratings for nDatalyze Corp. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is NDATF stock?

Check the beta and historical price range on this page to assess nDatalyze Corp.'s volatility relative to the broader market.